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ITALIAN ABSTRACT 
 
 
La Prostaglandina E2 (PGE2) è coinvolta in diversi processi fisiopatologici. PGE2 è una 
molecola chiave nel processo di cancerogenesi, essendo coinvolta nella proliferazione 
cellulare, nell'angiogenesi, nella sorveglianza immunitaria e nell’apoptosi.  
La sintesi di PGE2 richiede tre enzimi che agiscono in sequenza: la Fosfolipasi A2, la 
cicloossigenasi e la sintasi della prostaglandina E. La Fosfolipasi A2 (PLA2) permette il 
rilascio di acido arachidonico (AA) dai fosfolipidi di membrana, la cicloossigenasi (COX) 
converte l’AA a PGH2, che viene isomerizzato a PGE2 dalla sintasi della prostaglandina 
E (PGES). PGE2 viene rilasciato dalle cellule e interagisce con quattro distinti recettori, 
EP1, EP2, EP3 e EP4.  
Una sovra-espressione della forma inducibile di COX (Cox-2) e di PGES microsomiale-1 
(mPGES-1), con conseguente eccessiva produzione di PGE2, è stata osservata in vari 
tessuti tumorali, tra cui alcuni tumori cutanei. Una sovra-espressione di EP1 è stata 
osservata in tumori cutanei indotti da UVB. Varianti genetiche, situate nella regione del 
promotore dei geni codificanti per la prostaglandina sintasi-2 (PTGS2/COX2), PGES 
microsomiale-1 (mPGES-1), o per il recettore EP1 (PTGER1), potrebbero determinare 
alterazioni nella espressione genica, con una conseguente aumentata sintesi di PGE2 o 
alterata risposta a PGE2. Tali varianti potrebbero pertanto rappresentare fattori di rischio 
per lo sviluppo di tumore cutaneo non melanoma (non melanoma skin cancer NMSC) in 
individui riceventi trapianto d’organo (OTRs).  
Per determinare se polimorfismi in questi geni potessero costituire utili marcatori genetici 
di suscettibilità, contribuendo alla individuazione precoce di individui a maggiore rischio di 
NMSC, è stato eseguito uno studio caso-controllo. Due polimorfismi nel gene PTGS2, tre 
nel gene mPGES-1 e tre nel gene PTGER1 sono stati genotipizzati in 286 OTRs, 144 
casi NMSC e 142 controlli.  
L’allele –765G del gene PTGS2 è significativamente più frequente nei casi rispetto ai 
controlli [p=0.015; OR=9.59 (1.36-192.66)], suggerendo che questa variante possa 
rappresentare un fattore di rischio per lo sviluppo di tumori basocellulari (BCC) nei 
soggetti sottoposti a trapianto prima dei 50 anni.  
L’analisi dei polimorfismi –1760C>A (rs3810254), -1728G>A (rs3810255) e –1113C>T 
(rs2241359) della regione 5' prossimale del gene PTGER1 ha dimostrato che gli alleli 
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minori per queste varianti erano più rappresentati in individui con tumore squamocellulare 
(SCC), rispetto ai corrispondenti controlli sottoposti a trapianto prima dei 50 anni, ma la 
differenza non è risultata statisticamente significativa. Per verificare se una regione di 
1452 pb del 5' fiancheggiante il gene, e contenente i tre polimorfismi, esercitasse 
un'attività di promotore, è stata eseguita l’analisi funzionale in colture cellulari HeLa e 
HaCat (cheratinociti umani). Nonostante una debole attività di promotore sia stata 
osservata in cellule HeLa, non siamo stati in grado di dimostrare attività di promotore 
nelle cellule HaCat, anche dopo stimolazione con LPS.  
La regione del 5' fiancheggiante il gene mPGES-1 è stata analizzata mediante l’analisi 
degli eteroduplici per identificare nuove varianti. Tre polimorfismi, situati all'interno di 
regioni conservate del gene e riportati nel database NCBI come –664T>A (rs7873087),   
–663A>T (rs7859349) e –439T>C (rs7872802), sono stati identificati. Le distribuzioni 
genotipiche osservate hanno indicato completo linkage disequilibrium per i tre 
polimorfismi, e nessuna associazione con NMSC.  
In conclusione, l’allele -765C nel gene PTGS2 sembra rappresentare un fattore protettivo 
verso lo sviluppo di BCC negli individui sottoposti a trapianto prima dei 50 anni. L’analisi 
dei polimorfismi nella regione 5’ fiancheggiante i geni mPGES-1 e PTGER1 tende ad 
escludere l’ipotesi che varianti in queste regioni possano rappresentare fattori di rischio 
per la predisposizione a NMSC. 
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ENGLISH ABSTRACT 
 
 
Prostaglandin E2 (PGE2) is a prostanoid with a variety of bioactivities, and has been 
implicated in various pathologies. PGE2 appears as a key molecule in tumour formation, 
involved in cell proliferation, angiogenesis, immune surveillance, and apoptosis.  
PGE2 is produced via three sequential enzymatic reactions: release of arachidonic acid 
(AA) from membrane glycerophospholipids by phospholipase A2 (PLA2), conversion of 
AA to the unstable intermediate prostanoid PGH2 by cyclooxygenase (COX), and 
isomerization of PGH2 to PGE2 by prostaglandin E synthase (PGES). PGE2 is released 
from cells and it interacts with four distinct receptors, EP1, EP2, EP3, and EP4.  
Over-expression of the inducible form of COX (Cox-2) and microsomal-prostaglandin E 
synthase-1 (mPGES-1), resulting in excessive prostaglandin E 2 (PGE2) production,  has 
been observed in cancer of various tissues, including skin cancer. An over-expression of 
EP1 has been observed in skin cancer development induced by UVB. Alteration in gene 
expression, due to genetic variants located in the promoter region of the genes for 
prostaglandin synthase-2 (PTGS2/COX2), microsomal prostaglandin E synthase 
(mPGES-1), or prostaglandin E receptor 1 (PTGER1) may result in augmented PGE2 
synthesis or in altered response to PGE2, and could represent risk factors for the 
development of non melanoma skin cancer (NMSC) in organ transplant recipients 
(OTRs).  
To determine if polymorphisms in these genes can be useful genetic markers of 
susceptibility that may contribute to early detection of individuals at greater risk of NMSC, 
a case-control study was performed. Two polymorphisms in the PTGS2 gene, three in the 
mPGES-1 gene, and three in the PTGER1 gene were genotyped in 286 OTRs, 144 
NMSC cases and 142 controls. 
Allele –765G in the PTGS2 gene was more frequent in cases than in controls [p=0.015, 
OR=9.59 (1.36-192.66)], suggesting that this variant might represented a risk factor in the 
development of basal cell cancer (BCC) in individuals undergoing transplantation before 
50 years of age.  
Analysis of polymorphisms –1760C>A (rs3810254), -1728G>A (rs3810255), and             
–1113C>T (rs2241359) in the 5’ proximal region of the PTGER1 gene showed that minor 
alleles of these variants were more represented in individuals with squamous cell cancer 
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(SCC), when compared to matched controls who underwent transplantation before 50 
years of age, but the difference did not reach significance. To verify if the 1452 bp 
fragment of the 5’ flanking region, which contains the three polymorphisms could exert 
promoter activity, we performed functional analysis in HeLa and HaCat cultured cells. 
Although a weak promoter activity was observed in HeLa cells, we were unable to 
demonstrate any promoter activity in HaCat cells, even after LPS stimulation. 
The 5’ flanking region of the mPGES-1 gene was screened by heteroduplex analysis to 
identify new variants. Three polymorphisms, located within conserved regions of the 
gene, and reported in NCBI databases as –664T>A (rs7873087), –663A>T (rs7859349) 
and –439T>C (rs7872802), were identified. The observed genotype distributions 
indicated complete linkage disequilibrium for the three polymorphisms, and no 
association with NMSC was observed. 
In conclusion, allele –765C in the PTGS2 gene seems to represent a protection factor 
against the development of BCC tumours in individuals undergoing transplantation before 
50 years of age. Analysis of polymorphisms in the 5’ regions of the mPGES-1 and 
PTGER1 genes did not support the hypothesis that variants in these regions could play a 
major role in NMSC predisposition.  
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INTRODUCTION 
 
 
Organ transplant recipients (OTR) are at increased risk of developing both systemic and 
cutaneous cancers, with an overall increased risk 3- to 4-fold greater than that in the 
general population (Sheil, 1992). The most common types of post-transplantation cancers 
include skin cancer, post-transplantation lymphoma, cervical carcinoma, and Kaposi’s 
and other types of sarcomas (Penn, 2000a; Penn, 2000b; First and Peddi, 1998) (Tab. 1 
and Fig. 1). 
Other epithelial malignancies, including urogenital tract, gastrointestinal tract, laryngeal, 
and bronchial carcinomas, occur at an increased rate, in contrast to the rates of cancer 
prevalent in the general population, such as breast and prostate cancers, which are not 
increased in transplant recipients (Penn and Brunson, 1988).  
 
 
  
Frequencies of tumors after transplantation
skin & lips 36%
Lymphomas 
17%
lung 
5,5%
Kaposi
4,5%
                                                                              
 
 
 
Tab. 1 and Fig. 1: De Novo Tumours in Organ Transplant 
Recipients Reported to the Cincinnati Transplant Tumour
Registry (First and Peddi 1998) 
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1. Skin cancers 
Skin cancers are the most frequent malignancies after organ transplantation (Euvrard et 
al., 2003; Ulrich et al., 2004), with 95% of them being non melanoma skin cancers 
(NMSC) (Fig. 2), especially squamous cell carcinomas (SCC) and basal cell carcinomas 
(BCC). The incidence of some rare tumours (such as melanoma, Merkel cell Carcinoma 
and Kaposi's sarcoma) is also increased in this group of patients compared with the 
general population (Dreno, 2003; Zafar et al., 2008).  
 
 
     
NMSC 90%
melanoma 7%
neuroendocrine
2%  Kaposi sarcoma 
      1%
 
 
Malignant melanoma: is a type of cancer arising from the melanocyte cells of the skin. 
Although transplant recipients appear to be at lower risk for melanoma than for other skin 
cancers, the risk has been reported to be increased by a factor of 1.6 to 3.4 in Europe 
(Jensen et al., 1999; Birkeland et al.,1995;) and by a factor of 2 to 4 in Australia, as 
compared with the risk in the general population (Bouwes-Bavinck et al., 1996 ; Sheil et 
al., 1987). 
Kaposi’s sarcoma: the incidence is much higher in transplant recipients than in non 
immunosuppressed people (by a factor of 84 to 500) (Euvrard et al., 2003). This cancer 
usually starts within the dermis but can also form in internal organs. Cutaneous sarcomas 
other than Kaposi’s sarcoma have been reported in transplant recipients (Penn, 1995). 
However, the small number of reported cases prevents conclusions about their incidence 
and whether it is higher in such patients than in the general population. These tumours 
include angiosarcomas, fibroxanthomas, leiomyosarcomas, and dermatofibrosarcoma 
protuberans. 
Fig. 2: Frequency and type of skin cancer occurring in OTR patients 
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Merkel cell carcinoma: this rare type of skin cancer develops from neuroendocrine cells 
(hormone-making cells that resemble nerve cells in some ways) in the skin. These 
cancers are thought to be caused in part by sunlight exposure. The lesion develops an 
average of 7.5 years after transplantation, and is usually located on the head or neck and 
on the arms (Euvrard et al., 2003). 
Skin lymphomas: they affect up to 5 percent of all transplant recipients. Seventy percent 
of cutaneous lymphomas are B-cell lymphomas in origin, presenting as single or multiple 
papules or nodules on the face, trunk, or limbs, which are occasionally ulcerated. The 
other 30 percent of cutaneous lymphomas are T-cell lymphomas in origin, manifested 
clinically as mycosis fungoides, erythroderma, or hemorrhagic lesions, usually with 
generalized lymphadenopathy (Euvrard et al., 1992).
 
Keratoacanthomas: these are growths that are found on sun-exposed skin. Although 
they may start out growing quickly, their growth usually slows down. Many 
keratoacanthomas shrink or even go away on their own over time without any treatment. 
But some continue to grow, and a few may even spread to other parts of the body. 
Because their growth is often hard to predict, many skin specialists think it is safest to 
consider them as a form of squamous cell skin cancer. 
 
1.1 Non melanoma skin cancer 
Non melanoma skin cancers affect cells different from melanocytes: keratinocyte cells, 
fibroblasts, endothelial cells, although usually NMSC refers to basal cell carcinomas 
(BCC) and squamous cell carcinomas (SCC). 
The first sign of BCC is often a small red, pink or pearly lump, which appears on 
previously normal skin (Fig. 3a). The lump is often dome-shaped. However, BCCs can 
vary in shape and colour. They usually grow very slowly. 
 
 
       Fig. 3: Examples of Basal Cell Carcinoma (BCC) (a) and Squamous Cell Carcinoma (SCC) (b) 
a b 
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SCC typically starts as a small crusted or scaly area or skin with a red or pink base (Fig. 
3b).  It may grow into a lump which may look like a wart. An SCC may ulcerate or bleed 
from time to time. However, an early SCC can vary in shape, appearance and colour. 
Squamous cell carcinoma in situ, also called Bowen disease, is the earliest form of 
squamous cell skin cancer. "In situ" means that the cells of these cancers are still entirely 
within the epidermis and have not yet spread to the dermis. 
The incidence of NMSC increases steadily with time after transplantation, and varies in 
the United States and Western Europe from 5% to 10–27% to 40–60% at 2, 10 and 20 
years, respectively (Kasiske et al., 2004; Ramsay et al., 2007; Bordea et al., 2004).  
Several studies have shown a 2- to 4-fold higher incidence in heart transplant recipients 
(HTR) as compared with kidney transplant recipients (KTR) (Ulrich et al., 2004; Fortina et 
al., 2000; Otley et al., 2005). Studies on skin cancers in liver transplant recipients (LTR) 
are more numerous (Ulrich et al., 2004; Euvrard et al., 2006); current data suggest that 
their incidence could be similar to KTR (Otley et al., 2005; Euvrard et al., 2006). 
In OTR the ratio of SCC to BCC (4/1) is reversed compared with the population at large, 
and this reversal increases with decreasing latitude, sunlight exposure, and length of 
follow-up (Euvrard et al., 2003; Ulrich et al., 2004). While age-matched KTR and HTR 
show similar ratios, LTR seem to have a higher rate of BCC. 
 
 
2. Risk factors in NMSC 
2.1 UV radiation and skin cancer     
 Ultraviolet (UV) radiation in sunlight is the most 
prominent and ubiquitous known physical 
carcinogen in our natural environment. It is highly 
genotoxic but does not penetrate the body any 
deeper than the skin. The shorter wavelengths of 
this spectrum, UVB (290–320 nm) is absorbed 
within the epidermis and upper dermis and causes 
erythema and sunburns (Fig. 4).  
Like all organisms regularly exposed to sunlight, the human skin is extremely well 
adapted to continuous UV stress. Well-pigmented skin is clearly better protected than 
white Caucasian skin. The sun-seeking habits of white Caucasians in developed 
Fig. 4: UV wavelength and skin  
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countries are likely to have contributed strongly to the increase in skin cancer observed 
over the last century. Skin cancer is by far the most common type of cancer in the U.S.A. 
and Australia, which appears to be the result of an unnatural displacement of people with 
sun-sensitive skin to sub-tropical regions. Although campaigns have been successful in 
informing people about the risks of sunlight exposure, general attitudes and behaviour do 
not yet appear to have changed to the extent that trends in skin cancer morbidity, and the 
corresponding burden on public healthcare, will be reversed. The relationship between 
skin cancer and regular sun exposure was suspected by physicians in the late 19th 
century, and subsequently substantiated in animal experiments in the early part of the 
20th century. UV radiation was found to be highly genotoxic, and DNA repair mechanisms 
proved to be crucial in fending off detrimental effects such as mutagenesis and cell death. 
In fact, around 1940 it was shown that the wavelength dependence of mutagenicity 
paralleled the UV absorption by DNA. In the 1970s research on UV carcinogenesis 
received a new impetus from the arising concern about a possible future depletion of the 
stratospheric ozone layer: the resulting increases in environmental UV loads were 
expected to raise skin cancer incidences. Epidemiological studies in the last decades of 
the 20th century have greatly refined our knowledge on the aetiology of skin cancers. 
Molecular analyses of gene mutations in skin carcinomas have identified UV radiation as 
the cause (de Gruijl et al., 2001).  
UV radiation induces redox imbalance affecting cell membrane, cell cycle, and the rate of 
apoptosis in both human melanocytes and  keratinocytes (Larsson et al.,  2005).  
UVA is absorbed within the skin and gives rise to photosensitizing reactions by interaction 
with endogenous chromophores. In these reactions, singlet oxygen is initially formed, 
followed by other reactive oxygen species. Singlet oxygen alters signal transduction 
within a cell, and various studies have demonstrated the activation of several genes 
following this “trigger”, including oxygenase-1 (Basu-Modak and Tyrrell, 1993), NF-κB 
(Vile et al., 1995a), and STAT1 (Vile and Tyrrell, 1995b). Convincing evidence has been 
presented for singlet oxygen-mediated oxidation of cholesterol, lipids, DNA, and proteins 
in cell culture models (Girotti, 2001; Wright et al., 2003; Phillipson et al., 2002). Such 
reactions lead to impaired cellular functions, and the reaction products might contribute to 
DNA damage and increased risk of malignant transformation. For example, UVA appear 
to induce genomic instability in immortalized human keratinocyte cells (HaCat) by an 
oxidative stress mechanism (Phillipson et al., 2002). Moreover, several reports have 
documented beneficial effect of antioxidants in protecting skin cells against UV irradiation, 
as well as endogenous protection by subsequent induction of manganese superoxide 
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dismutase and glutathione (GSH) peroxidase in human dermal fibroblasts  (Meewes et al., 
2001). UVB caused no immediate detectable oxidative damage in normal human 
melanocytes (MCs); however, a significant effect on cell viability can be observed 24 h 
after irradiation. Further, the rate of apoptosis appears increased after UVB exposure 
which can be an indication of a consequence of direct DNA damage. 
 
2.2 Other factors that increase risk of NMSC development 
Genetic predisposition and nonenvironmental factors such as skin type can exacerbate 
the risk posed by solar radiation. Fair-skinned individuals who have received high levels 
of sunlight exposure are at the greatest risk for developing these cancers. In addition, 
men are about twice as likely to develop NMSC as women.  
- Fair-skinned people, with light colored hair and eyes, or those more likely to burn than 
tan are at the greatest risk for developing these cancers. People who sunburn easily and 
never tan run the highest risk of skin cancer. The incidence of tumour goes up with 
increasing UV exposure over the USA (Scotto and Fears, 1987). Black-skinned people 
are less likely to get skin cancer, but they can be at risk on the soles of the feet and 
palms of the hands. 
- A history of sunburn or recreational exposure to sunlight increases the risk of BCC.  
Risk is especially high if you had several episodes of sunburn in childhood. 
- Male gender; men are about 2 times as likely as women to have basal cell cancers and 
about 3 times as likely to have squamous cell cancers of the skin (Hoban et al., 2002). 
This is thought to be due mainly to higher sun exposure. 
- HPV infections; epidemiological and experimental studies have overwhelmingly 
confirmed human papillomaviruses (HPV) as important causal agents in NMSC 
carcinogenesis (Harwood and Proby, 2002; Aubin et al., 2003). HPV is found in many 
NMSCs, and probably contributes to the molecular mechanisms of carcinogenesis, 
particularly certain viral subtypes. A recent study indicates that cutaneous infections with 
HPV5 and HPV8 may result in an increased risk of SCC development in transplant 
recipients (Stockfleth et al., 2004).  
- Genetic predisposition; the observed phenotypic diversity between individuals reflects 
the presence of subgroups of individuals that have a strong genetic predisposition, and 
may require only moderate exposure to UV to initiate tumour development, as well as 
others that may require intense, repeated exposures because of robust protective still 
unknown genetic factors. 
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It has been reported the prevalence of NMSC in affected families is far greater than in the 
normal population (Herity et al., 1989). The trait appeared to be dominantly inherited, and 
NMSC developed at an earlier age in subsequent generations, possibly because of a 
change in sun exposure habits (Czarnecki et al., 1992). 
The concept of genetic susceptibility is complex. Genes are described as susceptibility 
genes when the mutant or variant gene is more common in the affected phenotype, or as 
genetic modifiers when the mutant or variant gene influences the severity of the 
phenotype. The selection of candidate susceptibility genes for NMSC is influenced by the 
various effect of UV light, this  being the mayor risk factor. Thus, such genes are selected 
from pathways involved in DNA repair of UV-related adducts, defence against oxidative 
stress, immune modulation, tanning, and other related biochemical activities. Many 
approaches have focused on studying allele frequencies and genotype distributions of 
polymorphic candidate genes in case-control studies.  
The human glutathione S-transferase (GST) supergene family comprises a group of 
genes encoding enzymes involved in the detoxification of a variety of reactive and 
mutagenic compounds, including the products of UV-induced oxidative damage. 
Polymorphisms in the Glutathione-S-transferase (GST) have been reported associated to 
NMSC (Heagerty et al., 1994; Lira et al., 2006), and interaction between GST allelic 
variants and CYP1A1 genotypes have been reported to show a higher risk of developing 
NMSC, especially SCC, in transplant patients, indicating that allelism and/or interactions 
between allelic variants at other loci may also influence the risk of NMSC (Lira et al., 
2006). An association between the class II antigen HLA-DR7 and the occurrence of skin 
cancers has also been described. Conflicting results have been reported concerning HLA-
A11: both negative and positive associations have been reported (Jensen et al., 1999). 
Exposure to UV has pleiotrophic effects, both direct and indirect, in skin. It induces 
covalent bonds between adjacent pyrimidines generating photoproducts, such as 
cyclodipyrimiidine dimers (TT) and pyrimidine-pyrimidine lesions. DNA repair is important 
in modulating the effects of UV exposure. Thus, xeroderma pigmentosum patients 
defective in nucleotide excition repair systems are susceptible to multiple BCC, and they 
also exhibit an increased frequency of UV signature mutations in important genes, 
including PTCH and p53 (Grossman and Wei, 1995; D’Errico et al., 2000; Reinfenberger 
et al., 2005). Association of polymorphisms of PTCH gene with NMSC predisposition has 
also been reported (Asplund et al., 2005; Strange et al., 2004).    
- Immunosupression; there is a well-defined increased risk of malignacies after solid 
organ transplantation (Kessler et al., 2006; Herrero et al., 2005a; Mithoefer et al., 2002; 
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Zafar et al., 2008) (Tab. 1). As increasing number of patients are transplanted and  graft 
survival improves, the incidence of post-transplantation cancers has consequently 
increased (Moloney et al., 2006; Herrero et al., 2005b). 
 
3. NMSC in transplant patients 
Factors in OTRs that confer increased susceptibility to NMSC are similar to those in the 
general population, but the tumours behave more aggressive, occur at a younger age, 
are more numerous, grow more rapidly, and metastasize early in the transplant group 
(Sheil et al., 1985; Liddington et al., 1998; Glover et al., 1994; Martinez et al., 2003;  
Kovach et al., 2005) Whereas OTR share similar determinants with immunocompetent 
individuals, their specific tumour burden appears to be linked to the type, dosage and 
duration of immunosuppression. The most important predisposing factors include fair 
color of their skin, eyes and hair, as well as the susceptibility to sunburn. Cumulative 
ultraviolet radiation (especially UVB) is the primary responsible carcinogen for the 
induction of NMSC, as suggested by the fact that the lesions almost exclusively appear 
on UV-exposed skin sites, and are more numerous in patients living in sunny countries. 
Age is also an important risk factor: in OTR patients, the risk ratio was reported to be 
around 12-fold higher in patients receiving grafts beyond age 55, compared to patients 
with grafts received before the age of 34 (Otley et al., 2005; Ulrich et al., 2004). While the 
higher prevalence of NMSC in HTR has long been thought to be due to greater 
immunosuppression, it seems that the older age of HTR at transplantation is the main 
reason (Fortina et al., 2000; Otley et al., 2005). Indeed, the dosages of 
immunosuppressants in HTR and KTR at the occurrence of skin cancer were recently 
found to be similar (Euvrard et al., 2006). 
The duration of immunosuppression seems to be involved on the multiplicity of lesions, 
since the number of lesions per patient over the same follow-up period is significantly 
higher in KTR versus HTR (Euvrard et al., 2006). This could be due to the younger age at 
transplantation of KTR, who have a longer exposure to immunosuppression at the 
occurrence of the first SCC. Patients older at transplantation, even if they develop the first 
SCC sooner, have a shorter immunosuppression time at the first NMSC, and are more 
similar in this respect to the general population. 
Genetic susceptibility to skin cancer may be particularly important in immunosuppressed 
individuals, who have the additional insult of long-term immunosuppression and 
increased susceptibility to HPV infections.  
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One possible mechanism by which UV light promotes carcinogenesis is its ability to 
induce prostaglandins formation, which may then function as a tumour promoter, or may 
enhance initiation because of their ability to act as oxidants (Vanderveen et al., 1986; 
Cerutti and Trump, 1999; Hruza  and Pentland,  1993; Grewe et al., 1993).  
 
4. Prostaglandin E 2 
Among the various prostaglandins (PGs), PGE2 appears as a key molecule in tumour 
formation, because of its effects on cell proliferation, angiogenesis, immune surveillance, 
and apoptosis (Ali et al., 2005; Langsenlehner et al., 2006; Campa et al., 2004; Cao and 
Prescott, 2002; Navarro et al., 2008) (Fig. 5).  
 
 
In epithelial tumours of the mammary gland, PGE2 may stimulate the formation of 
proangiogenic factors such as VEGF (vascular endothelial growth factor), which promotes 
tumour-associated angiogenesis. Solid malignancies are made up of cells that produce 
signals that act both in a paracrine and autocrine manner as depicted.  
PGE2 can contribute to tumour development through several mechanisms including (i) 
promotion of angiogenesis, (ii) inhibition of apoptosis, (iii) increased invasiveness/motility, 
and (iv) modulation of inflammation and immune responses (Chun and Surh, 2004). The 
molecular mechanism responsible for PGE2-induced colorectal cancer cell migration and 
invasion is known to involve an epidermal growth factor receptor (EGFR)–
phosphatidylinositol 3-kinase–Akt pathway. However, the mechanisms by which PGE2 
modulates apoptosis are still largely unknown. One potential mechanism with regard to its 
regulation of programmed cell death is that PGE2 reduces the basal apoptotic rate by 
increasing the level of antiapoptotic proteins such as BCL-2, or other members of the 
Fig. 5: Schematic representation of 
PGE2 possible participation in 
cancerogenesis (modified from Chun 
and Surh, 2004) 
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BCL gene family, such as MCL-1. In general, PGE2 suppresses immunosurveillance by 
down-regulating T and B cell proliferation, cytotoxic activity of natural killer cells, and 
cytokines such as IL-12 and tumour necrosis factor α  (Wang and Dubois, 2004) (Fig. 6). 
 
 
 
Fig. 6:  Possible mechanisms of PGE2 tumorigenesis (modified from Wang and DuBois, 2004) 
 
 
Depending on the tissue context, PGE2 signalling may affect growth (proliferation, 
terminal differentiation, and survival), angiogenesis, invasiveness, and/or immune 
surveillance. 
The levels of extracellular-active PGE2 are regulated by metabolic clearance along an 
energy-dependent uptake mechanism across the cell plasma membranes through 
prostaglandin transporter (PGT), members of the family of organic anion transporting 
polypeptides (OAT), which exhibit an energy-dependent lactate/PG exchange activity. 
The first and rate-limiting step in the intracellular degradation of PG is catalyzed by the 
NAD+ dependent enzyme 15-Hydroxyprostaglandin Dehydrogenase (15-PGDH), which 
catalyzes the oxidation of the PG 15-hydroxy group to a 15-keto group. 15-PGDH was 
found to be down-regulated in human epithelial tumours and to show tumour suppressor 
activity in epithelial cancers (Müller-Decker and Fürstenberger, 2007). 
PGE2 is produced via three sequential enzymatic reactions: release of arachidonic acid 
(AA) from membrane glycerophospholipids by phospholipase A2 (PLA2), conversion of 
AA to the unstable intermediate prostanoid PGH2 by cyclooxygenase (COX), and 
isomerization of PGH2 to PGE2 by prostaglandin E synthase (PGES) (Fig. 7 and Fig. 8). 
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As autocrine and/or paracrine signalling molecules, PGE2 is released from cells and it 
interacts with distinct G protein-coupled receptors (GPCR) characterized by seven-
transmembrane domains. PGE2 may bind to the four GPCR isoforms EP1, EP2, EP3, 
and EP4.  
 
             
   
 
 
5. Cyclooxygenase 2 (Cox-2) 
An over-expression of Cox-2, which results in excessive prostaglandin production, has 
been observed in human skin actinic keratoses (premalignant UV-induced skin lesions), 
SCCs,  BCCs, in human epidermal keratinocytes after UVB injury, in squamous cell skin 
cancer, in human epidermal cancer cell lines (Buckman et al., 1998; Subbaramaiah and 
Dannenberg, 2003; An et al., 2002; Higashi et al., 2000; Hull,  2005; Tripp, et al., 2003), 
and in early stages of carcinogenesis in a wide variety of tissues.  A mouse model of 
UV-induced skin carcinogenesis utilizes SKH-1 hairless mice, which initially develop 
benign papillomas and then SCCs after chronic UVB exposure. In this model, Cox-2 has 
also been shown to be over-expressed early on in UV-induced hyperplastic skin as well 
as in papillomas and SCCs  (An et al., 2002; Pentland et al., 1999). Moreover, COX-2 
has been shown to be transiently induced in human and mouse skin after a single acute 
Fig. 8:  PGE2 signalling in cancer. The stars correspond 
to COX2, and mPGES-1 over-expression in a wide range 
of premalignant and malignant epithelial tumours (Müller-
Decker and Fürstenberger, 2007). 
Fig. 7: schematic representation of the 
prostaglandins biosynthetic pathway from membrane 
phospholipids (modified from Chell et al., 2006) 
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exposure to UV radiation (An et al., 2002; Tripp et al., 2003; Akunda et al., 2007; Fischer 
et al., 2007).  
Coincident with Cox-2 up-regulation, primarily in the basal layer, is an increase in PGE2 
production and an increase in keratinocyte proliferation and apoptosis (Akunda et al., 
2007; Fischer 2007; Trifan and Hla, 2003; Cao and Prescott, 2002).  
To demonstrate that UV induction of Cox-2/PGE2 expression is important for UV-induced 
skin responses and carcinogenesis, various nonsteroidal anti-inflammatory drugs 
(NSAIDs), which are inhibitors of COXs, have been used in the SKH-1 and other mouse 
models. Both indomethacin, a general Cox inhibitor, and celeCoxib, a Cox-2-selective 
inhibitor, when fed to mice in the diet, were found to significantly inhibit UV-induced 
tumorigenesis in terms of number of tumours/mouse and tumour size (Pentland et al., 
1999; Fischer et al., 1999). Similarly, topical treatment of mice with celeCoxib 
immediately following each UV irradiation, reduced the number of tumours/mouse and 
tumour size (Wilgus et al., 2003). Papillomas that did develop on mice treated with UV 
plus topical celeCoxib had reduced levels of PGE2and reduced the number of 
proliferating cells and p53-positive cells compared with papillomas from mice not treated 
with celeCoxib (Wilgus et al., 2003).  Even when celeCoxib treatment (dietary or topical) 
was initiated after tumours had developed and UV exposures were stopped, celeCoxib 
was able to inhibit new tumour formation, although there was little or no regression of 
established tumours (Pentland et al., 1999; Wilgus et al., 2003; Fischer et al., 2003). 
Moreover, it has been shown that regular users of NSAIDs have a reduced risk of 
developing actinic keratoses and cutaneous SCCs (Butler et al., 2005). 
Currently, three Cox isoenzymes are known: Cox-1, Cox-2 and Cox-3. Cox-3 is a splice 
variant of Cox-1 which retains intron 1 and has a frameshift mutation. 
In terms of their molecular biology, Cox-1 and Cox-2 are of similar molecular weight 
(approximately 70 and 72 kDa respectively), and share approximately 60-65% amino-acid 
identity with each other; Cox-1 orthologs (without the signal peptide) share approximately 
70-95% amino-acid identity across vertebrate species, and Cox-2 orthologs share 70-
90%. The most significant difference between the isoenzymes, which allows for selective 
inhibition, is the substitution of isoleucine at position 523 in Cox-1 with valine in Cox-2. 
The relatively smaller Val523 residue in Cox-2 allows access to a hydrophobic side-pocket 
in the enzyme (which Ile523 sterically hinders). Drug molecules, such as DuP-697 and the 
Coxibs derived from it, bind to this alternative site and are considered to be selective 
inhibitors of Cox-2 (Mifflin  and Powel, 2001, 
http://www.medpubinc.com/newsletters/RPL.pdf ) (Fig. 9). 
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Cox-1 is normally constitutively 
expressed in most tissues and its 
expression usually does not vary 
greatly in the adult animal (Smith et al., 
2000). The PG products of COX-1 are 
involved in normal physiologic 
functions, such as maintenance of the 
gastric mucosa and regulation of renal 
blood flow (Fig. 10).  
Cox-2 expression, on the other hand, is 
generally undetectable in most 
unperturbed adult tissues, but can be 
highly induced by a variety of agents, 
including proinflammatory agents and mitogens (Taketo, 1998; Smith et al., 2000; Hull, 
2005).  
To date, Cox-2 has been determined to contribute to tumorigenesis and to the malignant 
phenotype of tumour cells via the inhibition of apoptosis, increased angiogenesis and 
invasiveness, and modulation of inflammation and immunosuppression (Dempke et al., 
2001; Wang and Dubois 2006; Sahin et al., 2009). 
 
5.1 PTGS2 gene 
The PTGS2 gene (also named COX2) maps to chromosome 1(1q25.2-25.3), contains ten 
exons (Fig. 11) and codes for a protein of 604 aa: the inducible cyclooxygenase Cox-2 
(http://www.genecards.org/cgi-bin/carddisp.pl?gene=PTGS2). PTGS2 is an immediate-early 
response gene whose expression is highly induced in response to hormones, pro-
Fig. 10: Overview of prostaglandin (PG) synthesis and main functions 
(Wang and DuBois, 2006).  
 
Fig. 9. A:  Diagrammatic representation of the of Cox-
1 and Cox-2 in the ER membrane. In the central 
portion of each monomer is shown a cutout section 
demonstrating NSAID binding to the active site. In the 
case of COX-1, the active site is narrower allowing 
access only to NSAIDs with smaller side chains. Cox-
2 specific NSAIDs contain larger side chains not 
accommodated by the Cox-1 pocket. B: Diagrammatic 
representation of the molecular structure of 
flurbiprofen, a nonselective NSAID, and celecoxib, a 
Cox-2 specific NSAID (Mifflin  and Powel, 2001, 
http://www.medpubinc.com/newsletters/RPL.pdf ) 
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inflammatory cytokines, growth factors, oncogenes, carcinogens and tumour promoters 
(Smith et al., 2000; Hull, 2005). 
 
 
 
 
PTGS2 expression is regulated at both transcriptional and post transcriptional level, and  
the deregulation of PTGS2 expression observed in carcinogenesis can in part be due to 
functional changes affecting these regulatory regions of the gene.  
The promoter region of the PTGS2 gene contains several key cis-acting regulatory 
elements, including a canonical TATA box, and various response elements for nuclear 
factor kB (NK-kB), PEA3, AP2, nuclear factor interleukin-6 (NF-IL6), Sp1, adenosine 3’, 
5’-cyclic-monophosphate-response element (CRE), c-MYB, transforming growth factor β 
(TGFβ), and others (Fig. 12). Depending on the stimulus and the cell type, these 
transcription factors can play a decisive role in the regulation of COX-2 transcription 
(Shao et al. 2000; Dixon, 2003a; Chun and Surh, 2004; Yang and Bleich 2004). 
Current studies have demonstrated that post-transcriptional regulation plays a central role 
in the regulatory mechanisms of PTGS2 expression (Harper and Tyson-Capper, 2008). 
The PTGS2 3′UTR is larger than average, encompassing ~2.5 kb, and has many 
interesting features. It has several polyadenylation signals, only two of which are 
commonly used, resulting in mRNAs of ~2.8 or ~4.6 kb. The proximal polyadenylation 
signal has a non-consensus CPSF (cleavage polyadenylation specificity factor) binding 
site (AUUAAA), followed by putative upstream enhancer elements (USEs). It is likely that 
regulation occurs in part here, resulting in two mRNAs with different RNA metabolism. 
The significance of the different tissue distributions of these isoforms has not yet been 
addressed, and tissue specificity might play a role in PTGS2 polyadenylation site choice 
(Cok and Morrison, 2001).  
The 3′UTR also has 22 repeats of adelylate and uridylate-rich (AU-rich) elements (AREs), 
composed of the sequence 5’-AUUUA-3. This AU-rich region is highly conserved in both 
sequence and location among human, mouse, rat, chicken, pig, cow and sheep PTGS2 
mRNA transcript, implying that the function of the ARE have been evolutionary 
conserved. This element, which is present within the 3'UTRs of many proto-oncogene and 
 Fig. 11: Schematic representation of PTGS2 gene (also named COX2) and corresponding mRNA (Chandrasekharan 
and Simmons, 2004). 
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cytokine mRNAs, confers post-transcriptional control of expression. There are many 
different polypeptides that specifically interact with AREs from rapidly degraded mRNAs. 
These regulatory trans-acting factors include several cytoplasmic mRNA-binding proteins 
proposed to be involved with the destabilization, stabilization, or mRNA processing and 
nucleocytoplasmic transport (Cok and Morrison 2001; Dixon 2003a; Dixon et al., 2003b). 
Regulation of gene expression at a post-transcriptional level is also mediated by 
microRNAs, short single-stranded non-coding RNAs, which affect stability and translation 
of their target mRNAs (Jing et al., 2005). 
 
 
 
 
 
Fig. 12: Schematic representation of the proximal region of human PTGS2 promoter. The TATA box is shown as a box and 
the transcription binding sites are depicted as bars and circles. The transcription start site  (+1) is indicated by an arrow. 
 
5.1.1 PTGS2 polymorphisms –765G>C and 8473T>C 
One common polymorphisms in the promoter region of the PTGS2 gene (-765G>C) (Fig. 
13) has been reported to alter promoter activity (Papafili et al., 2002, Zhang et al., 2005). 
Polymorphism -765G>C (rs 20417) is located at a putative Sp1 binding site and it has 
been shown that allele -765C have significantly lower promoter activity compared with -
765G in human lung fibroblasts cells. This polymorphism has been associated to 
myocardial infarction and stroke, to asthma risk, and to the risk of esophageal cancer 
(Cipollone et al., 2004; Papafili et al., 2002; Zhang et al., 2005).  
One common polymorphism in the 3’UTR region (8473T>C) (Fig. 13) has been described 
and reported associated to an increased risk for non-small cell lung cancer, colorectal 
adenoma, and breast cancer (Langsenlehner et al., 2006; Campa et al., 2004; Cox et al., 
2004). In contrast, three other studies described a protective effect of the same genetic 
variant against lung cancer (Hu 2005; Sorensen et al., 2005; Park et al., 2006). The 
functionality of polymorphism is currently unknown and the reason for this discrepancy 
could be due to ethnic differences between studies. The 8473T>C (rs 5275) 
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polymorphism could be in linkage disequilibrium with other causal genetic variants, and 
this linkage disequilibrium would likely be different across different ethnic populations. 
 
 
 
 
 
 
6. Prostaglandin E synthase (PGES) 
Despite a rapidly expanding body of information on the structures, expression and 
regulatory functions of various eicosanoid biosynthetic enzymes during the last decade, 
little has been learned about the molecular identity of PGES until very recently.  
Three forms of PGES have been identified to date, cytosolic PGES, microsomal PGES-1 
and microsomal PGES-2 (Tanioka et al., 2000; Jakobsson et al., 1999; Tanikawa et al., 
2002). 
Cytosolic PGES (cPGES) is constitutively expressed in many tissues and preferentially 
coupled with COX1 in the maintenance of tissue homeostasis (Tanioka et al., 2000). 
Microsomal PGES-1 (mPGES-1) is induced by proinflammatory stimuli (Jakobsson et al., 
1999), and displays a marked preference for being functionally coupled with COX2 
(Mancini et al., 2001), contributing to a variety of physiological and pathologic conditions, 
such as fever, inflammation, and reproduction (Murakami et al., 2000; Murakami et al., 
2002; Yamagata et al., 2001). Transcript for mPGES-2 is more abundantly distributed in 
the brain, heart, skeletal muscle, kidney and liver than in other tissues (Tanikawa et al., 
2002). In contrast to the marked inducibility of mPGES-1, mPGES-2 is constitutively 
expressed in various cells and tissues and is not increased appreciably during tissue 
inflammation or damage (Murakami et al., 2003). When transfected in several cell lines, 
mPGES-2 is coupled with both COX-1 and COX-2, leading to PGE2 production 
(Murakami et al., 2003) (Fig. 14). Since the mature mPGES-2 exists as an N-terminally 
truncated form that is dispersed in the cytoplasm, mPGES-2 can function as a cytosolic 
enzyme rather than a membrane-bound enzyme. 
 Fig. 13: Schematic representation of PTGS2 gene showing the relative position of polymorphisms -765G>C and 
8473T>C. 
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Fig. 14: Coupling between two COX isoforms and three PGES enzymes (modified from Murakami and Kudo, 2006). 
 
The mPGES-1 enzyme is a member of the MAPEG (membrane associated proteins 
involved in eicosanoid and glutathione metabolism) superfamily, together with FLAP (five-
lipoxygenase-activating protein) and leukotriene C4 synthase, proteins which are also 
involved in arachidonic acid metabolism. The primary structures of proteins from several 
species show a high degree of sequence homology (Fig. 15). mPGES-1 also shows 
significant homology with other MAPEG superfamily proteins, including MGST-1, MGST-
2, MGST-3, 5-lipoxygenase-activating protein (FLAP) and leukotriene C4 synthase 
(LTCS), with the highest homology being found with MGST-1 (~40%). mPGES-1 requires 
glutathione (GSH) as an essential cofactor for activity (Jakobsson et al., 1999; Murakami 
et al., 2000). Two-dimensional crystals of purified mPGES-1 demonstrate that the 
enzyme structure is trimeric (Thorén et al., 2003). 
 
 
Fig. 15: Primary amino acid sequences of mPGES-1. Residues conserved in all four species are boxed. The Arg residue 
essential for catalytic activity is shown by asterisk, and the putative MK-886-binding motif is underlined (Murakami and 
Kudo, 2006).  
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6.1 mPGES-1 gene 
The human mPGES-1 gene maps to chromosome 9q34.3, is 14.7 kb long and contains 
three exons (http://www.genecards.org/cgi-bin/carddisp.pl?gene=PTGES&search=ptges) 
(Fig. 16). Although this gene is probably co-stimulated with COX2, the promoter region of 
mPGES-1 lacks a TATA box and contains different transcriptional elements not present in 
the COX2 promoter (Fig. 17). In the mPGES-1 proximal promoter region there are two 
GC boxes, two tandem Barbie boxes, and an Aryl Hydrocarbon Response element 
(AHR), consistent with other members of the MAPEG and Glutathione-S-transferase 
families (Forsberg et al., 2000). The 3’ region of the mPGES-1 gene lacks the AUUUA 
mRNA instability sequences that are found in the COX-2 gene. More detailed analysis of 
~1800 bp upstream of the human and mouse mPGES-1 gene reveals binding sites for 
C/EBPa and b, AP- 1, and two tandem GC-boxes as well as two progesterone receptor- 
and three glucocorticoid receptor-responsive elements (Naraba et al., 2002).  Of these 
sites, the proximal GC boxes are most critical for the inducible promoter activity. 
Expression of mPGES-1 is in part regulated by the mitogen-activated protein kinase 
pathways (Han et al., 2002), where the kinases may switch to the proximal GC boxes in 
the mPGES-1 promoter, leading to inducible mPGES-1 transcription (Naraba et al., 
2002).  Additionally, mPGES-1 expression is ablated in lipopolysaccharide (LPS)-
stimulated macrophages from NF-IL-6-deficient mice (Uematsu et al., 2002), indicating 
the participation of this transcription factor in the induction of mPGES-1. Both the Sp1 
and Sp3 proteins are important for the basal expression of mPGES-1 (Ekström et al., 
2003). 
 
 
 
 
 Fig. 16: Schematic representation of mPGES-1 gene  
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  Fig. 17: Regulatory elements of the human microsomal prostaglandin E synthase-1 (mPGES-1) and cyclooxygenase-2    
  promoters. AP-1 or -2, activator protein-1 or -2; c/EBP, CCAAT/enhancer-binding protein; GR, glucocorticoid receptor;    
  NFκB, nuclear factor κB; PR, progesterone receptor; Sp1, specificity protein-1 (Sampey et al., 2005). 
 
 
Although the steady-state expression of mPGES-1 in normal rat tissues is very low, 
administration of lipopolysaccharide (LPS) leads to a dramatic increase in mPGES-1 
expression in various tissues (Murakami et al., 2000; Mancini et al., 2001; Yamagata et 
al., 2001). Stimulation of various cultured cells with pro-inflammatory stimuli leads to a 
marked elevation of mPGES-1 expression, often with concomitant induction of COX-2 
(Jakobsson et al., 1999; Murakami et al., 2000; Mancini et al., 2001). Transfection of 
mPGES-1 in combination with COX-2, but not with COX-1, into Human Embryonic Kidney 
293 cells (HEK293 cells)  leads to cellular transformation, which is manifested by 
aggressive cell growth, piling up and aberrant morphology, with a concomitant increase in 
PGE2 (Murakami et al., 2000). Mutations affecting expression or activity of mPGES-1 
could result in alteration in the response to specifics stimuli, leading to a differential 
inflammatory reaction, and could be associated to many diseases where inflammation 
plays an important role.  
An over-expression of mPGES-1 has been reported in cancer cells of various human and 
mouse tissues, such as non-small cell lung cancer (NSCLC), head and neck squamous 
cell carcinoma, squamous cell carcinoma of the penis, and papilloma lesions of the skin 
(Yoshimatsu et al., 2001; Cohen et al., 2003; Golijanin et al., 2004; Neumann et al., 
2007).  
 
6.1.1 mPGES-1 polymorphisms 
Screening of the coding sequence of the gene identified two non-synonymous 
polymorphisms, only one likely to be functionally relevant, present among African-
Americans and not among the Caucasian populations. (Bigler et al., 2007) 
Polymorphisms in the coding sequences of the gene are rare and and largely of low allele 
frequency, suggesting little tolerance of genetic variations that could affect normal 
prostaglandin functions. 
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Few polymorphisms in the non coding sequence of the gene have been reported in 
relation with hypertension and breast cancer with no positive results (Iwai et al., 2004; 
Abraham et al., 2009).  
To our knowledge, the possible association of mPGES-1 genetic variants on the risk of 
NMSC has never been investigated.  
 
 
7. EP receptors 
PGE2 acts via four cell-surface seven-transmembrane G-protein-coupled receptors 
known as E prostanoid (EP) receptors, designated EP1 through EP4. Prostanoid 
receptors are generally expressed in cell surface plasma membranes, although recent 
data suggests some EP receptor subtypes to be also associated with the nuclear 
membrane. 
 In particular, the perinuclear localization of native EP1 receptor protein has been 
reported in porcine cerebral microvascular endothelial cells, as well as cloned EP1 in 
Swiss 3T3 fibroblasts (Bhattacharya et al., 1998).  Other receptors (particularly EP3 and 
EP4) have since also been suggested to be functionally expressed in the nuclear 
membranes of neonatal porcine brain and adult rat liver cells (Bhattacharya et al., 1999). 
The presence of nuclear EP receptors therefore implies that prostanoids may be capable 
of acting intracellularly in a novel form of autocrine signalling with a potentially  greater 
capacity to influence nuclear events, as well as their established ability to signal in a 
conventionally autocrine and paracrine way.  
Although little information exists about the expression and function of the EP receptors in 
the skin, the differential expression of these receptors during the development of UVB 
induced SCC in both experimental animals and humans indicates that these receptors 
are important in mediating the effects of prostaglandins in UVB-induced SCC.  
The possible role of the EP receptors in the photocarcinogenesis process is proposed in 
Fig. 18. Induction of COX-2 expression by UV irradiation results in increased production 
of prostaglandin E2 (PGE2). PGE2 binds to and activates four G protein-coupled 
receptors, of which EP1, EP2 and/or EP4 appear to be important for the effect of PGE2 in 
UV-induced skin damage and carcinogenesis. 
Signalling through the EP receptors results in the induction of various genes, including 
oncogenes, cytokines and growth factors, which then lead to inflammation with infiltration 
and activation of inflammatory cells in the dermis, induction of angiogenesis, vasodilation 
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and vascular permeability, leading to edema, increased keratinocyte proliferation and a 
reduction in apoptosis. All of these downstream effects of Cox-2 over expression and 
PGE2 signalling promote the development of UV-induced skin carcinogenesis 
(Rundhaugand Fischer, 2008). 
 
 
 
 
 
 
 
In particular, an increase in the level of EP1 receptor expression was observed in UVB-
induced benign papillomas and SCC in murine skin (Lee et al., 2005) and 
immunohistochemical analysis has demonstrated that EP1 is expressed by differentiated 
keratinocytes in murine epidermis(Tober et al., 2006). 
Moreover, the inhibition of the EP1 receptor through topical application of a specific EP1 
antagonist, ONO-8713, successfully decreased the infiltration of neutrophils into the skin 
in response to acute UVB exposure, and significantly reduced UVB-induced tumour 
development (Tober et al., 2006).  
 
7.1 PTGER1 gene 
The EP1 receptor is coded by the PTGER1 gene which maps to chromosome 19p13.1. 
This gene is 2897bp long and contains three exons (http://www.genecards.org/cgi-
bin/carddisp.pl?gene=Ptger1) (Fig. 19).  
 
Fig 18: possible role of the EP receptors in the 
photocarcinogenesis process (Rundhaug and Fischer, 
2008) 
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The presumed promoter region of the mouse EP1 receptor gene does not contain a 
TATA box or consensus sites for mammalian CCAAT-binding proteins, but does contain 
several GC-box-like motifs. These features are characteristic for many TATA-less 
promoters. In the proximal region of the transcription start site, there is also one 
consensus AP-1 site (TGAGTCA) and three AP-2 sites (GSSWGSCC) (Batshake et al., 
1995) (Fig. 20). 
 
 
Fig. 20: Nucleotide and deduced amino acid sequence of the 5’ of the mouse EP, receptor gene. The arrow indicates the 
transcription initiation site. Nucleotides are numbered relative to the transcription initiation site (+ 1) The potential binding 
sites for transcription factors AP-1 and AP-2 are single and double underlined, respectively (from Batshake et al., 1995). 
 
 
Cloning of the human EP1 receptor has revealed a protein of 402 amino acids with a 
predicted molecular weight of approximately 42 kDa (Watabe et al., 1993). Like the other 
EP receptors, it is a seven-transmembrane G-protein-coupled receptor (Fig. 21). 
 Fig. 19: Schematic representation of PTGER1 gene  
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7.1.1 PTGER1 polymorphisms  
Screening of the coding sequence of the human gene identified two non-synonymous 
polymorphisms, only one likely to be functionally relevant, present among African-
Americans and not among the Caucasian populations (Bigler et al., 2007). 
Association studies regarding polymorphisms in the PTGER1 gene have only been 
reported in relation to aspirin intolerant asthma (AIA) in the Korean population, where one 
common polymorphism in the downstream region of the gene (rs2241363) appeared to 
be associated to a lower risk of AIA (Park et al., 2010). 
Although different studies suggest the possible involvement of the EP1 receptor in skin 
tumorigenesis (Lee et al., 2005; Tober et al., 2006), to our knowledge, the possible 
association of PTGER1 genetic variants with the risk of NMSC has not yet been 
investigated thus far. 
 
 
8. Molecular mechanisms by which UVB light can induce 
PTGS2, mPGES-1 and PTGER1 expression 
Several studies have shown a link between prostaglandin production and the initiation 
and progression of skin carcinogenesis (Fischer et al., 1999; Wilgus et al., 2003; Chun et 
al., 2007). UVB activates a number of signalling pathways leading to inflammatory gene 
 Fig. 21: EP1 receptor protein (from 
http://www.caymanchem.com/images/curr
ents/005/human-EP1-color.jpg) 
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expression, a process referred to as ‘the UV response’ (Heck et al., 2004). Initially 
characterized by activation of the immediate early genes, c-fos and c-jun and various 
transcription factors including NFκB (Heck et al., 2004), more recent studies have 
demonstrated that PI3K/Akt and MAP kinase signalling are also key to the response 
(Bode and Dong, 2003),  and this response appears to be differentiation-dependent. In 
fact, while the ERK1/2, JNK, p38 MAP kinases and Akt were activated by UVB in 
undifferentiated cells, in differentiated cells, only JNK and p38 kinase were activated. 
Inhibition of p38 MAP kinase has been shown to suppress UVB-induced inflammation in 
mouse skin including expression of proinflammatory cytokines and Cox-2 production 
(Hildesheim et al., 2004; Kim et al., 2005). Black et al., 2008 observed that UVB-induced 
PTGS2 expression is regulated via p38 kinase, as well as JNK and Akt kinase, and that 
UVB-induced expression of mPGES-1 was suppressed by JNK and PI3K/Akt inhibition. 
UVB light stimulates the release of arachidonic acid from keratinocyte cell membranes, 
and increases the expression of PTGS2 and various prostaglandin synthases and EP1 
receptor (Fig. 22). This indicates that UVB not only upregulates the capacity of 
keratinocytes to generate PGE2, but also their responsiveness to this prostaglandin.  
 
 
 
 
 
        Fig. 22: Summary of the effects of UVB on the PGE2  biosynthetic pathway (Black et al., 2008). 
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The deregulation of the expression of PTGS2, mPGES-1 and PTGER1 can in part be due 
to functional changes of the regulatory elements of gene expression. 
This study was designed to investigate if polymorphisms of PTGS2, mPGES-1 and 
PTGER1 (encoding the EP1-receptor) can constitute risk factors for the development of 
NMSC in OTRs, and to determine if these polymorphisms can be useful genetic markers 
of susceptibility allowing to early highlight individuals at greater risk of NMSC, after 
transplantation. 
In order to achieve this goal, polymorphisms were genotyped to define their association 
with the phenotype. 
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MATERIALS AND METHODS 
 
 
1. Subjects 
Transplanted patients (kidney, heart and liver) undergoing immunosuppressive therapy 
with a functioning graft and a minimum of one year of follow-up since transplantation, and 
affected by at least one histologically proven NMSC within 10 years from transplantation, 
were considered cases. Controls were OTRs free from skin cancer for a minimum of 10 
years after transplantation. For each patient, basic demographic data, date of 
transplantation and of the visit, long term immunosuppressive therapy, type of skin 
cancers, skin type, eye and hair colour were recorded. Long term maintenance 
immunosuppression consisted in a combination of one or two immunosuppressive drugs 
(azathioprine, cyclosporine, mycophenolate mofetil and tacrolimus) with oral 
methylprednisolone, according to current protocols (Halloran, 2004). A total of 286 solid 
organ transplant recipients, including 144 cases and 142 controls, were selected for the 
study (Tab. 2).  
Skin tumours were classified by pathological criteria. 
 
 
 
 Cases Controls Total 
Sex  
   M/F (total patients)  
 
125/19  
 
117/25  
 
242/44  
Type of transplantation   N°   N°   N° 
   Kidney 
   Heart 
   Liver 
107 
  31 
    6 
120 
  21 
    1 
227 
  52 
    7 
Mean ± SD age at transplantation (years) 
(Range) 
45.33 ± 13.34 
(17.84-72.87) 
45.01 ± 13.04 
(12.28-63.59)   
46.2 ±12.99 
(12.28-72.87) 
Type of cancers (cases)  N°  
   Basal Cell Carcinoma (BCC) 
   Squamous Cell Carcinoma (SCC)  
   Bowen 
   Keratoacanthoma 
   Merkel cell carcinome  
   Others 
63 
68 
  4 
  3 
  3 
  3 
 
 
 
 
Tab. 2: Study group characteristics 
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2. Molecular methods  
DNA was extracted from peripheral blood leukocytes by standard salting out method 
(Miller et al., 1988). 
 
2.1 Genetic analysis  
2.1.1 PTGS2  
To determine –765G>C (rs20417) genotype, Amplification Refractory Mutation System-
PCR (ARMS-PCR) was performed. Tab. 4 describes the primers used, designed 
according to Ensembl, ID ENSG00000073756. As a polymerase chain reaction (PCR) 
control, we co-amplified a SPINK 1 gene fragment of 317 bp. 
Genotyping of polymorphism 8473 T>C (rs5275) was performed by Restriction 
Generating PCR (RG-PCR) (Gasparini et al., 1992), using a Forward modified primer that 
creates a Bcl I restriction site when allele 8473C is present (Tab. 4). The digestion 
products were analysed by 3% agarose gel electrophoresis. 
 
2.1.2 mPGES-1 
Search for new polymorphisms in the mPGES-1 promoter was performed by amplifying a 
1166 bp region, spanning position −1193 upstream the starting site of transcription to 
position -27, in seven partially overlapping fragments. Primer sequences were designed 
based on the mPGES-1 genomic sequence available from Ensembl, ID 
ENSG00000148344 (Tab. 3). 
Amplified genomic fragments were screened for mutations using heteroduplex analysis 
by electrophoresis in Mutation Detection Enhancement gels (MDE Gel Solution, Biospa 
Società Prodotti Antibiotici S.p.a., Milan, Italy), with 15% (w/v) urea, at 250 V for 16–24 h. 
Amplified fragments with altered migration pattern were directly sequenced at the BMR 
Genomics of Padua.  
Polymerase chain reaction (PCR) and restriction fragment length polymorphism (PCR-
RFLP) analysis were performed to genotype polymorphism –664T>A (rs7873087), using 
primers and endonuclease as detailed in Tab. 4. Amplification products of four individuals 
homozygous -664AA (minor allele) and 25 random individuals with genotype –664TA 
were directly sequenced at the BMR Genomics of Padua.  
Genotyping of polymorphism –439T>C (rs7872802) was performed by RG-PCR, using a 
Forward modified primer that creates a Rsa I restriction site when allele –439C is present. 
Tab. 4 describes the primers used, designed according to Ensembl, ID 
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ENSG00000148344. The digestion products were analysed by 3% acylamide gel 
electrophoresis. 
 
 
Primers Amplified fragment 
pF: 5’-gctggaattacaggtgtgag-3’ 
Fragment 1 pR: 5’-tgagacccatttcaggcttc-3’ 276 bp 
pF: 5’-ctcaggaagtcagtggagcc-3’ Fragment 2 pR: 5’-ggagagacgctaacctgctg-3’ 282 bp 
pF: 5’-gagagtttgtttcgtcccct-3’ Fragment 3 pR: 5’-gtgactatgtggcaaaaggg-3’ 301 bp 
pF: 5’-gaagggcccctctgtatact-3’ 
Fragment 4 pR: 5’-cacactcagcctggacaatg-3’ 231 bp 
pF: 5’-catggatgtctttaggggtg-3’ Fragment 5 pR: 5’-ctgccttctagggaatgatg-3’ 225 bp 
pF: 5’-ataatcaccacgtgcagagg-3’  Fragment 6 pR: 5’-gagaaagacaagcagttgcc-3’ 224 bp 
pF: 5’-ccacatgctcccacactgta-3’ Fragment 7 pR: 5’-tgtgatcagctcgacagagg-3’ 286 bp 
 
 
2.1.3 PTGER1 
Polymorphisms of the PTGER1 gene (coding for the EP1-receptor) were selected from 
the SNPper database. Polymorphisms –1760C>A (rs3810254), -1728A>G (rs3810255), –
1113C>T (rs2241359) in the PTGER1 gene were genotyped by PCR-RFLP.  
Tab. 4 describes primers and restriction enzymes used. Primers were designed 
according to Ensembl, ID ENSG00000160951. 
 
Tab. 4: Primers and endonucleases used for genotyping polymorphisms of the PTGS2, mPGES-1 and PTGER1 genes. 
Undelined characters are the modified bases. 
 
Gene Polymorphism Primers Restriction 
enzyme 
(bp) 
 
-765G>C 
PF1:5′aggagaatttacctttcccc3′  
PF2:5′aggagaatttacctttcccg3′ 
pR:5′ggctgtatatctgctctatatg3’ 
 
SpinkF:5’tttgagttcatcttacaggtgag3’ 
SpinkR:5’cagggtcatatggcagatggcagcaa3’ 
 
__ 
 
206  
PTGS2 
8473T>C pF: 5’-gtttgaaattttaaagtacttttgat-3’ 
pR: 5’-atgtctagatttcaaattattgtttcattgc-3’ 
Bcl I 147 
–664T>A  pF: 5’-gagagtttgtttcgtcccct-3’ 
pR: 5’-gtgactatgtggcaaaaggg-3’ 
FblI 301  
mPGES-1 
–439T>C  pF: 5’-agactgagtgtaggggcgta-3’ 
pR: 5’-ctgccttctagggaatgatg-3’ 
RsaI 140 
–1760C>A pF: 5’- tcttagtgtgtgaggctgcg-3’ 
pR: 5’-gccacagcgagtcatatcct-3’ 
HhaI 198 
-1728A>G pF: 5’-tgccagtgtgaccctacttc-3’ 
pR: 5’-gccacagcgagtcatatcct-3’ 
HinfI 180 
 
 
PTGER1 
–1113C>T pF: 5’-ctgcaactacaggccccccg-3’ 
pR: 5’-cactgcctgggatgtggggt-3’ 
SacII 188 
 
Tab. 3: Primers used for the amplification of segments in the proximal 5’ region of the mPGES-1 gene 
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2.2 Functional analysis 
The promoter activity of the proximal 5’ flanking region of the PTGER1 gene was 
investigated in vitro by Luciferase reporter gene constructs transiently transfected in 
cultured cells of Mycoplasma free HeLa cells and human keratinocyte cell line HaCat.  
 
2.2.1 Reporter gene constructs 
Two fragments of 1452 bp (from –2461 bp to –1012 bp) and  212 bp (from –1221 bp to –
1012 bp), respectively, were amplified using forward and reverse primers that introduce a 
restriction site for endonuclease Xho I and Hind III, respectively (Tab. 5).  
Amplified products and pGL3 basic Luciferase vector (LUC, Promega) were digested with 
endonucleases Xho I and Hind III (Fig. 23), and purified from agarose gel after 
electrophoresis, using Qiagen purification kit. Quantification of the purified products was 
determined using NanoDrop®ND-1000. Ligation of amplified products to pGL3 basic 
Luciferase vector was performed overnight using the T4 ligase (Promega). JM109 
competent cells (Stratagene) were transformed with the ligation products. Sequences of 
positive identified clones were confirmed by sequencing. 
 
 
Tab. 5: Primers used for the amplification of the two fragments of the PTGER1 gene. Primers are modified (underlined 
characters) to introduce a restriction site for endonuclease Xho I and Hind III  
 
 
Gene Fragment Primers 
1452 bp  pF:5’gcgctcgagagggcaattgcaggtgtaact3’ 
pR: 5’ctgaagctttctccggcaagccgcttc3’ 
 
PTGER1 212 bp pF:5’ gcgctcgagcaactccagggagctca 3’ 
pR: 5’ctgaagctttctccggcaagccgcttc3’ 
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2.2.2  Cell culture  
Cells were cultured in DMEM (Dulbecco Modified Eagle’s Medium) with 10% deactivated 
FCS (fetal calf serum), Glutamine 1%, 100U/ml Penicillin-100ug/ml Streptomycin at 37°C 
with 5% CO2.  
 
 
2.2.3 Transfections 
Cells were seeded in 24-wellplate at a density of 6x104 cell/well. When cultures achieved 
50-70% confluence, the cells were co-transfected with 1µg of LUC construct, together 
with 40ng of the plasmid pRL-null-vector, which contains the gene for Renilla reniformis 
luciferase (pRL), and serves as control for transfection efficiency. Negative control was 
obtained using pGL3-basic vector without any insert. Transfections were performed with 
SuperFect Transfection Reagent (Qiagen), according to the manufacturer’s instructions.  
Three hours after transfection, the medium was changed, and Hacat cells were cultured 5  
or 20h in the presence or absence of LPS (LPS 300ng/mL; LPS 100ng/mL; no LPS). 
Promoter functionality in HeLa cells was performed without LPS stimulation. After 
incubation, Firefly and Renilla lucifereses activity were measured using “Dual-Luciferase 
Reporter Assay System” (Promega), according to the manufacturer’s instructions. LUC 
and pRL activity were measured sequentially using a 20/20n luminometer (Turner 
Fig. 23: pGL3 basic vector red circles indicate the used endonucleases  
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Biosystem). Promoter activity was normalized by dividing LUC activity by pRL activity. 
Experiments were carried out in triplicate.  
 
 
3. Statistical analysis 
Genotypes for all polymorphisms were measured and the Epi Info software package 
(version 2003) was used for assessing association using 2x3 and 2x2 contingency tables. 
Chi-square test, with Yates’ correction or Fisher’s exact test was used for association. 
Odds ratio (OR) and the OR 95% confidence interval were also calculated. Single locus 
analysis was performed in the total group of NMSC. We also tested the hypothesis of 
association to SCC and BCC, since the etiology of SCC and BCC might be very different 
and by stratifying individuals by age < or > 50 years at transplantation, since age is an 
important risk factor for NMSC (Navarro et al., 2008). The correction of the p value 
threshold, by Bonferroni multiple test adjustment, is difficult to establish, since tests in the 
study group are not independent. We have accepted for single gene the threshold of 
0.05/5=0.01. 
Interaction among risk alleles was evaluated, by logistic analysis models, for 
polymorphisms –765G>C (rs20417) and -1728A>G (rs3810255) to assess the 
contribution to NMSC.   
The significance of functional results was determined by Student's T-test and p values 
were evaluated. Values are expressed in mean value ± standard deviation.  
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RESULTS 
 
1. PTGS2 
1.1 Genotype analysis 
Observed genotype distributions of the polymorphisms –765G>C and 8473T>C are 
summarized in Tab. 6. A frequency of 0.19 and 0.35 was observed for polymorphisms –
765G>C and 8473T>C, respectively, in the overall population sample. Single locus 
analysis of polymorphisms showed no differences in genotype distributions between 
cases and controls. Stratification of the population by age at transplant showed that, in 
BCC who underwent transplantation before 50 years of age, allele –765C was never 
present in homozygosity, and only one heterozygote case was found. Individuals with GG 
genotype appear to have a major risk of BCC development [(p=0.015; OR=10.31 (1.36-
209.74)] (Tab. 6).   
 
 
 
Tab. 6: genotype distribution of PTGS2 polymorphisms in cases and controls as total NMSC and stratified by BCC, SCC 
and age at transplant  
 
 
-765G>C 8473T>C 
 
GG GC CC Total p value TT TC CC Total p value 
Controls 95 41 6 142  64 59 19 142  
NMSC 97 38 9 144 0.7 57 66 17 140 0.64 
   BCC 46 14 3 63 0.61 28 26 8 62 0.99 
   SCC 43 20 5 68 0.61 24 34 8 66 0.39 
<50 years 
Controls 76 31 4 111  51 47 13 111  
NMSC 33 9 2 44 0.62 19 21 4 44 0.79 
   BCC 22 1 0 23 0.02a 13 8 2 23 0.65 
   SCC 9 8 2 19 0.14 5 12 2 19 0.22 
>50 years 
Controls 19 10 2 31  13 12 6 31  
NMSC 64 29 7 100 0.94 38 45 13 96 0.64 
   BCC 24 13 3 40 0.98 15 18 6 39 0.81 
   SCC 34 12 3 49 0.74 19 22 6 47 0.66 
a
 GG vs GC+CC p=0.015; OR=10.13 (1.36-209.74) 
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2. mPGES-1 
2.1 Search for polymorphisms  
Heteroduplex analysis of amplified fragments covering a region of 1166 bp of the 
proximal 5´ region of the gene was performed in 30 SCC, 30 BCC and 30 control 
individuals.   
Direct sequencing of fragments presenting altered migration pattern demonstrated three 
variants −664T>A (rs7873087), –663A>T (rs7859349) and –439T>C (rs7872802). 
 
2.2 Genotype and haplotype analyses 
NCBI database reported equal frequencies for the polymorphisms -663A>T and -664T>A, 
suggesting linkage disequilibrium between these two variants. This hypothesis was 
supported by sequence analysis of 4 homozyotes, and 25 random heterozygote 
individuals. Consequently, only polymorphism -664T>A was genotyped.  
Observed genotype distribution (Tab. 7) of polymorphism –439T>C indicated complete 
linkage disequilibrium also between this SNP and -664T>A (overall frequency=0.14). 
Single locus analysis showed no differences in genotype distributions between cases and 
controls, neither when analysing NMSC as a total group of cases, nor when stratified by 
type of tumour or by age at transplant (Tab. 7). Haplotype analysis of the overall 
population showed no differences in haplotype distributions between cases and controls 
(Tab. 8). 
 
Tab. 7: genotype distribution of mPGES-1 polymorphisms in cases and controls as total NMSC and stratified by BCC, SCC 
and age at transplant 
mPGES-1 genotype Controls NMSC  BCC SCC 
TT
-664-AA-663-TT-439 82 82  35  39 
TA
-664-AT-663-TC-439 27  27 11 14 
AA
-664-TT-663-CC-439 3  1 0 1 
Total 112 110 46 54 
p value 
 0.61 0.53 0.92 
<50 years 
TT
-664-AA-663-TT-439 64 19 8 10 
TA
-664-AT-663-TC-439 21 9 4 4 
AA
-664-TT-663-CC-439 3 1 0 1 
Total 88 29 12 15 
p value 
 0.74 0.66 0.79 
>50 years 
TT
-664-AA-663-TT-439 18 63 27 29 
TA
-664-AT-663-TC-439 6 18 7 10 
AA
-664-TT-663-CC-439 0 0 0 0 
Total 24 81 34 39 
p value 
 0.78 0.69 0.95 
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Tab. 8: distribution of mPGES-1haplotypes in cases and controls as total NMSC and stratified by BCC, SCC and age at 
transplant 
 
mPGES-1 haplotype Controls NMSC  BCC SCC 
T
-664-A-663-T-439 191 191  81  92 
A
-664-T-663-C-439 33  29 11 16 
p value 
 0.73 0.64 0.88 
<50 years 
T
-664-A-663-T-439 149 47 20 24 
A
-664-T-663-C-439 27 11 4 6 
p value 
 0.66 0.77 0.59 
>50 years 
T
-664-A-663-T-439 42 144 61 68 
A
-664-T-663-C-439 6 18 7 10 
p value 
 0.99 0.94 0.82 
 
 
 
3. PTGER1 
3.1 Genotype and haplotype analyses 
The three most frequent polymorphisms in the proximal 5’ region of the gene were 
selected from the SNPper database: –1760C>A (rs3810254), -1728G>A (rs3810255), 
and –1113C>T (rs2241359). The frequency reported in NCBI database for these common 
variants is 0.14 (CEU low coverage panel). 
Genotype distribution for the three polymorphisms is reported in Tab. 9. A frequency of 
0.14 was observed for the three polymorphisms, showing complete linkage disequilibrium 
for all the three variants. Haplotype analysis of the overall population showed no 
differences in haplotype distributions between cases and controls (Tab. 10).  
Genotype distribution showed an association trend (p=0.049) to SCC in individuals who 
underwent transplantation before 50 years of age. Individuals carrying the three minor 
alleles were more represented in cases than in controls.  
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Tab. 9: genotype distribution of PTGER1 polymorphisms in cases and controls as total NMSC and stratified by BCC, SCC 
and age at transplant 
 
PTGER1 genotype Controls NMSC  BCC SCC 
CC
-1760-GG-1728-CC-1113 86 76 29  39 
CA
-1760-GA-1728-CT-1113 27  32 16 14 
AA
-1760-AA-1728-TT-1113 0  2 1 1 
Total 113 110 46 54 
p value 
 0.22 0.09 0.32 
<50 years 
CC
-1760-GG-1728-CC-1113 69 19 7 11 
CA
-1760-GA-1728-CT-1113 20 9 5 3 
AA
-1760-AA-1728-TT-1113 0 1 0 1 
Total 89 29 12 15 
p value 
 0.13 0.15 0.049 
>50 years 
CC
-1760-GG-1728-CC-1113 17 57 22 28 
CA
-1760-GA-1728-CT-1113 7 23 11 11 
AA
-1760-AA-1728-TT-1113 0 1 1 0 
Total 24 81 34 39 
p value 
 0.86 0.66 0.93 
 
 
 
Tab. 10: distribution of PTGER1haplotypes in cases and controls as total NMSC and stratified by BCC, SCC and age at 
transplant 
 
PTGER1 haplotype Controls NMSC  BCC SCC 
C
-1760-G-1728-C-1113 199 184 74  92 
A
-1760-A-1728-T-1113 27  36 18 16 
p value 
 0.23 0.11a 
 
0.58 
 <50 years 
C
-1760-G-1728-C-1113 158 47 19 25 
A
-1760-A-1728-T-1113 20 11 5 5 
p value 
 0.19b 
 
0.19c 
 
0.37 
>50 years 
C
-1760-G-1728-C-1113 41 137 55 67 
A
-1760-A-1728-T-1113 7 25 13 11 
p value 
 0.93 0.69 0.85 
 
a
 OR=0.56 (0.28-1.13); b OR=0.54 (0.23-1.31); c OR=0.48 (0.15-1.66) 
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3.2 Functional analysis  
Functional analysis of the proximal 5’ of the gene where the three polymorphisms are 
located was performed by two constructs containing 1452 bp and 212 bp, respectively. 
Both constructs showed promoter activity when transiently transfected in HeLa cells (Fig. 
24). When HaCat cells were transiently transfected in the presence/absence of LPS, the 
two constructs didn’t show promoter activity (Fig. 25-26). LPS stimulation with 300ng/mL 
or 100ng/mL did not change these results. 
 
   
Fig. 24: functional analysis in HeLa cells of two regions of the proximal 5’region of PTGER1. The pGL3 basic vector-
RAVER1 promoter construct has been used as positive control. 
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Fig. 25: functional analysis of the 1452bp region of 5’proximal of PTGER1 in HaCat cells in the presence/absence of LPS 
for 20h.  
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Fig. 26: functional analysis of the two regions of the proximal 5’region of PTGER1 in HaCat cells in the presence/absence 
of LPS for 5h. 
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DISCUSSION 
 
 
The involvement of PGE2 in tumorigenesis, by promoting cell survival, cell growth, 
migration, invasion and angiogenesis, is supported by multiple lines of evidence. The 
synergic action of cyclooxygenase (Cox), and prostaglandin E synthase (PGES) is 
required for the synthesis of PGE2, which exerts its effects by interacting with four 
receptors (EP1-4). 
Until recently, COX expression was believed to be the major determinant of PGE2 levels, 
but recent data indicate that multiple levels of control exist for the regulation of PGE2 
production and signalling. In addition to regulation via COX enzymes, PGE2 synthesis 
can be regulated via expression of specific prostaglandin E synthases (PGES), which act 
on the COX product, prostaglandin H2, to produce PGE2 (Chell et al., 2006 ; Park et al., 
2006b). The cellular response to PGE2 can also be regulated via the differential 
expression of the four PGE2 receptors (EP1–4), which activate distinct downstream 
signalling responses (Chell et al., 2006; Hull et al., 2004). An understanding of these 
levels of regulation (and response to) of PGE2 synthesis may reveal novel strategies for 
prevention and/or treatment of cancer. Genetic association studies can also provide 
insights into pathogenic and protective mechanisms, and identify new molecules and 
pathways which may become targets for pharmacological intervention. Moreover, genetic 
association studies could contribute to the identification of clinical and genetic markers of 
susceptibility that could allow early detection of individuals at highest risk to diseases, in 
order to focus on them with preventive efforts, subjecting them to a closer follow up, a 
more effective health education, and possibly preventive drug therapy. 
The inducible form of COX (Cox-2) and microsomal-PGES-1 (mPGES-1) are over-
expressed in cancer of various tissues, and PGE2-receptors (EP1-4) appear differentially 
expressed during skin cancer development induced by UVB, with an over-expression of 
EP1 (Lee et al., 2005). Early response genes are often regulated at both, transcriptional 
and post transcriptional levels, and their deregulation can in part be due to functional 
changes affecting the regulatory regions of the genes. Transcription process is complex, 
and requires the co-ordinated action of multiple regulatory proteins through complex 
protein–DNA and protein–protein interactions (Orphanides and Reinberg, 2002). 
Variation in the DNA sequence may potentially alter the affinities of existing protein–DNA 
                                                                                                                            Discussion 
 
43 
 
interactions or, indeed, recruit new proteins to bind to the DNA, altering the specificity and 
kinetics of the transcriptional process (Tournamille et al., 1995; Knight et al., 1999). 
Alteration in gene expression due to genetic variants in PTGS2 (coding for Cox-2), 
mPGES-1, or PTGER1 (coding for EP1) may thus play a role in the predisposition of 
NMSC in OTRs.  
 
The present study was initially focused on polymorphisms -765G>C (rs20417) and 
8473T>C (rs5275) in the PTGS2 gene, since these common polymorphisms, located in 
the transcriptional and post-transcriptional regulatory regions, respectively, have been 
reported to be associated with various human malignancies (Zhang et al., 2005; 
Langsenlehner et al., 2006; Campa et al., 2004; Cox et al., 2004; Hu 2005; Sorensen et 
al., 2005; Park et al., 2006; Lira et al., 2007).  
In a previous study, OTRs and control cases were genotyped for polymorphisms              
–765G>C (rs20417) and 8473T>C (rs5275) in the PTGS2 gene and association of 
polymorphism –765G>C with a subgroup of NMSC was reported (Lira et al., 2007).  
In the present study, we extended the published report to a larger number of patients, 
and the selection of patients was done introducing the cut-off of 10 years after 
transplantation. In agreement with the former work, allele –765G in the PTGS2 gene 
seems to represent a risk factor in the development of BCC tumours in individuals 
undergoing transplantation before 50 years of age [p=0,015, OR 9.59 (1.36-192.66)]. We 
speculate that the protective effect of the counterpart, allele -765C, is probably abolished 
in elderly individuals, where the additive effects of risk factors accumulation and 
diminished DNA repair capacity exert stronger effects. The correction of the p value 
threshold, by Bonferroni multiple test adjustment, is difficult to establish, since tests in the 
study group are not independent. We have accepted for single gene the threshold of 
0.05/5=0.01. In SCC, the effect of variant –765C is not evident, indicating that possibly 
environmental and genetic risk factors may play different roles in the outcome of these 
two types of lesions.  
The common polymorphism 8473T>C (rs5275) in the PTGS2 3’UTR region of the 
transcript has been described associated with several cancers in different ethnic 
populations with controversial results (Liu et al., 2010). Although different studies have 
reported the association of this variant to different malignancies, no information 
concerning its functionality is available. Previous work done in our laboratory, for the first 
time, analysed, in human keratinocyte cell line HaCaT the possible role of 8473T>C on 
PTGS2 gene expression. Transient transfection of construct vectors containing 8473T or 
C alleles did not showed any differences in gene expression (unpublished data). Since 
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regulation of PTGS2 gene expression depends on the type of cell and stimulus, it is 
possible that this variant may have no, or little, effect on post transcriptional regulation of 
PTGS2 expression in transformed human keratinocytes.  
One possible explanation for the discrepancy between association studies concerning 
8473T>C could be found in differences in linkage disequilibrium between these two SNPs 
across different ethnic groups, being polymorphism -765G>C the possible real causal 
genetic variant.  
It is noteworthy that, according to the HAPMAP data for the CEU population, the markers 
-765G>C and 8473T>C in the studied sample are in linkage disequilibrium (LD)  (D’= 
0.898 and r2 =0.351). In this study we did not observed any association of 8473T>C with 
the predisposition to NMSC. This result is not surprising since that, to identify an 
association of 8473T>C due to its linkage disequilibrium to -765G>C, a much greater 
number of individuals would be necessary. 
 
Despite a rapidly expanding body of information on expression and regulatory functions 
of PTGS2, little has been learned about mPGES-1 until very recently. Mutational analysis 
and association studies of the mPGES-1 gene have been reported in very few 
phenotypes. Polymorphisms in the non coding sequence of the gene have been reported 
in relation with hypertension and breast cancer, with no positive results (Iwai et al., 2004; 
Abraham et al., 2009). These data indicate that mPGES-1, such as other genes of the 
prostaglandin biosynthetic pathway, is highly conserved, with little tolerance for genetic 
variations. The prostaglandin synthesis pathway is vital for the normal functioning of the 
human body, and probably deleterious mutations have been evolutionarily selected 
against, and are rare in this gene (Bigler et al., 2007). 
The present case-control study describes the analysis of the mPGES-1 genetic variability 
in the proximal promoter region, in relation to NMSC after transplantation. Over-
expression of mPGES-1 has been observed in various cancer tissues (Yoshimatsu et al., 
2001; Cohen et al., 2003; Golijanin et al., 2004; Neumann et al., 2007). In particular, 
mPGES-1 expression was reported to be upregulated by UVB in undifferentiated and 
differentiated keratinocytes (Black et al., 2008). 
To our knowledge, this is the first study where the proximal promoter region of the gene 
has been systematically screened for polymorphisms, and where the possible association 
of mPGES-1 genetic variants with the risk of NMSC after organ transplantation have 
been analysed. Three polymorphisms, reported in NCBI databases as –664T>A 
(rs7873087),  –663A>T (rs7859349) and –439T>C (rs7872802), were identified.  
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All three polymorphisms are located within conserved regions of the gene, in four 
catarrhini primates (Homo sapiens, Pan troglodytes, Pongo pygmaeus and Macaca 
mulatta, Ensembl) sequences. Polymorphisms within conserved regions are likely to be of 
greater phenotypic significance than those within more divergent regions. As assessed by 
bioinformatic TESS Job, the presence of variants -664A and -663T may abolish a nuclear 
factor erythroid derived 2 (NF-E2) binding site, and may create a globin transcription 
factor-1 (GATA-1) binding site. NF-E2 is involved in the hemoglobin production 
(http://www.ncbi.nlm.nih.gov/omim/601490) and GATA-1, one of the six members of the 
GATA gene family, has a crucial role in normal human hematopoiesis 
(http://www.ncbi.nlm.nih.gov/omim/305371). Extensive survey of human tissue samples 
found that NF-E2 expression is not limited to erythropoietic organs. Expression in the 
colon and testis suggested that NF-E2 may participate in the regulation of genes other 
than globin (Chan et al., 1993). Mutations in GATA-1 have been found to have important 
clinical significance, and are directly linked to deregulated formation of certain blood cell 
lineages (Ciovacco et al., 2008). Although the potential effect of –664T>A, –663A>T and 
–439T>C polymorphisms on gene expression, no association with NMSC predisposition 
was observed. A minor effect of the mPGES-1 gene on the NMSC susceptibility cannot 
be ruled out, mainly due to the sample size analyzed.  
Although we evaluated the possible impact of the three sequence variants using in silico 
methods, functional studies are needed to define the influence of these polymorphisms 
on gene expression. 
 
The events downstream the enhanced PGE2 secretion that drive the carcinogenic 
process remain thus far largely undefined. PGE2-receptors (EP1-4) are differentially 
expressed during skin cancer development induced by UVB (Lee et al., 2005). An over-
expression of EP1, as a result of enhanced PGE2 levels, has been reported in both 
murine and human UVB-induced NMSC (Lee et al., 2005).  
Screening of the coding sequence of the human PTGER1 gene has identified two non-
synonymous polymorphisms, only one likely to be functionally relevant, present among 
African-Americans and not in the Caucasian populations (Bigler et al., 2007). The 
promoter region of the human PTGER1 gene has not yet been characterized. The 
presumed promoter region in the mouse gene showed one consensus AP-1 site and 
three AP-2 sites (Batshake et al., 1995), located in conserved regions of the gene, 
aligning Homo Sapiens and Mus Musculus sequences. Since the promoter activity of this 
region has not been tested in humans, we performed functional analysis to investigate if 
the region containing the analyzed polymorphisms has any transcriptional regulatory 
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function. Although a weak promoter activity was observed in HeLa cells, we were unable 
to demonstrate promoter activity of this region in HaCat cells even after LPS stimulation. 
Association studies regarding polymorphisms in the PTGER1 gene have only been 
reported in relation to aspirin intolerant asthma (AIA) in the Korean population, where one 
common polymorphism in the downstream region of the gene (rs2241363) appeared to 
be associated to a lower risk of AIA (Park et al., 2010). 
Although the possible involvement of the EP1 receptor in skin tumorigenesis has been 
suggested (Lee et al., 2005; Tober et al., 2006), the possible association of PTGER1 
genetic variants with the risk of NMSC has not yet been investigated thus far. 
We focused our attention on polymorphisms –1760C>A (rs3810254), -1728G>A 
(rs3810255), and –1113C>T (rs2241359), in the 5’ flanking region of the PTGER1 gene, 
since these variants have a reasonable frequency in the Caucasian population (0.14 in 
NCBI database), and/or are located within conserved regions of the gene. In particular     
the –1113C>T polymorphism is located in a putative binding site for a transcription factor    
(AP-2 in mouse and AP-2 alpha in human, TESS Job program 
http://www.bx.psu.edu/old/courses/bx-fall05/tess.html). Analysis of the three 
polymorphisms showed complete LD, and the haplotype containing the three minor 
variants was more represented in SCC individuals when compared to matched controls 
who underwent transplantation before 50 years of age, showing a trend of association in 
this subtype of patients.  
Additional association studies in an extended cohort of individuals or in other study 
populations would be necessary to verify the consistence of these results.  
 
Complex diseases, such as NMSC, can be due to the additive effects of different variants 
in several genes that, taken singly, would show only small effects on disease onset and 
pathogenesis. Thus, we have evaluated, in our cohort of patients, a possible synergistic 
effect of the polymorphisms analysed. Logistic analysis did not show evidence of any joint 
effect when possible risk alleles of PTGS2 and PTGER1 genes were considered. 
A big limitation of this work is the small sample size, which would have enabled us to 
identify only major at risk alleles, with a considerable possibility to fall in error type 2 (false 
negative). Although our results do not support the hypothesis that  polymorphisms in the 
mPGES-1, and PTGER-1 genes could represent important risk factors for NMSC 
development, these data could be useful for further meta-analysis studies, where also 
small cohort of patients are considered. The difficulties to include these results in meta-
analysis studies are mainly due to the inability to get them published, since ‘negative’ 
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(non-statistically significant) results are more likely to remain unpublished than studies 
with ‘positive’ (formally statistically significant) results. This is one of the biggest 
limitations of meta-analyses, since they often introduce publication bias. 
 
In conclusion, allele –765C in the PTGS2 gene seems to represent a protection factor 
against the development of BCC tumours in individuals undergoing transplantation before 
50 years of age, and this effect is probably abolished in elderly individuals where the 
additive effects of risk factor accumulation, along with a reduced DNA repair capacity 
exert stronger effects. Analysis of polymorphisms in the 5’ regions of the mPGES-1 and 
PTGER1 genes did not support the hypothesis that variants in these regions could play a 
major role in NMSC predisposition.  
 
 
 
.   
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